vs
Side-by-side financial comparison of BingEx Ltd (FLX) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
BingEx Ltd is the larger business by last-quarter revenue ($143.2M vs $75.5M, roughly 1.9× PUMA BIOTECHNOLOGY, INC.).
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
FLX vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.2M | $75.5M |
| Net Profit | $3.2M | — |
| Gross Margin | 10.8% | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 2.2% | — |
| Revenue YoY | — | 27.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.2M | — | ||
| Q4 25 | — | $75.5M | ||
| Q3 25 | $141.2M | $54.5M | ||
| Q2 25 | $143.0M | $52.4M | ||
| Q1 25 | $141.0M | $46.0M | ||
| Q4 24 | — | $59.1M | ||
| Q3 24 | $164.6M | $80.5M | ||
| Q2 24 | — | $47.1M |
| Q1 26 | $3.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $6.1M | $8.8M | ||
| Q2 25 | $7.5M | $5.9M | ||
| Q1 25 | $27.6M | $3.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.4M | $20.3M | ||
| Q2 24 | — | $-4.5M |
| Q1 26 | 10.8% | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | 11.1% | 77.7% | ||
| Q2 25 | 12.0% | 76.5% | ||
| Q1 25 | 10.0% | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | 11.3% | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.7% | ||
| Q3 25 | 1.4% | 17.6% | ||
| Q2 25 | 1.9% | 12.7% | ||
| Q1 25 | — | 8.7% | ||
| Q4 24 | — | 22.6% | ||
| Q3 24 | 4.0% | 27.4% | ||
| Q2 24 | — | -4.6% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.4% | 16.2% | ||
| Q2 25 | 5.2% | 11.2% | ||
| Q1 25 | 19.6% | 6.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.1% | 25.2% | ||
| Q2 24 | — | -9.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.26 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.12 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $0.41 | ||
| Q2 24 | — | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $561.1M | $97.5M |
| Total DebtLower is stronger | — | $22.7M |
| Stockholders' EquityBook value | — | $130.3M |
| Total Assets | $1.3B | $216.3M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $561.1M | — | ||
| Q4 25 | — | $97.5M | ||
| Q3 25 | $628.6M | $94.4M | ||
| Q2 25 | $499.4M | $96.0M | ||
| Q1 25 | $592.4M | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | $517.4M | $96.7M | ||
| Q2 24 | — | $96.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $130.3M | ||
| Q3 25 | — | $115.3M | ||
| Q2 25 | — | $104.7M | ||
| Q1 25 | — | $97.1M | ||
| Q4 24 | — | $92.1M | ||
| Q3 24 | — | $71.1M | ||
| Q2 24 | — | $48.5M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $216.3M | ||
| Q3 25 | $1.3B | $202.9M | ||
| Q2 25 | $1.2B | $194.9M | ||
| Q1 25 | $1.2B | $196.2M | ||
| Q4 24 | — | $213.3M | ||
| Q3 24 | $926.8M | $220.7M | ||
| Q2 24 | — | $205.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
